LAM
AZN icon

Lebenthal Asset Management’s AstraZeneca AZN Stock Holding History

Lebenthal Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,913
Closed -$237K – 353
2016
Q3 		$237K Buy
+2,913
New +$190K 0.03% 288

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Lebenthal Asset Management's AZN Position: Q4 2016 in Review

Lebenthal Asset Management sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 2,913 shares — an estimated $237K sold.

Lebenthal Asset Management first reported a position in AZN in Q3 2016 and held it in 1 quarter. The position peaked at $237K in Q3 2016. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

  • Lebenthal Asset Management reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
  • Lebenthal Asset Management sold 2,913 AstraZeneca shares in Q4 2016, an estimated $237K.
  • Lebenthal Asset Management first reported a position in AstraZeneca in Q3 2016 and held it in 1 quarter.
  • Lebenthal Asset Management's AstraZeneca position peaked at $237K in Q3 2016.
  • 450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on Lebenthal Asset Management's 13F filing for Q4 2016, filed 15 Feb 2017.